FDA-cleared profile

Lumify Diagnostic Ultrasound System

Philips Ultrasound, LLC · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Diagnostic ultrasound; assisted abdominal FAST acquisition and anatomical labeling

Clinical role
Image acquisition support and anatomical labeling
Images and patients
Ultrasound · Abdomen; Heart/Cardiovascular; Obstetric/Gynecologic; Musculoskeletal; Lung; Small parts
Key limitation
Keep in mind: FAST Auto Assist is Android-only, adult-limited and available with S4-1/C5-2 transducers. Anatomical labels do not establish free-fluid diagnosis or replace clinician interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Diagnostic ultrasound; assisted abdominal FAST acquisition and anatomical labeling
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Abdomen; Heart/Cardiovascular; Obstetric/Gynecologic; Musculoskeletal; Lung; Small parts Input: Live ultrasound from compatible Lumify transducers; FAST Auto Assist uses S4-1 or C5-2 abdominal imaging
  • Who uses it?Intended users: Qualified healthcare professionals trained in ultrasound
  • What does the software produce?Output: Ultrasound images and FAST organ/zone labels for right upper quadrant, left upper quadrant and suprapubic views
  • What is its most important limitation?Key limitation: FAST Auto Assist is Android-only, adult-limited and available with S4-1/C5-2 transducers. Anatomical labels do not establish free-fluid diagnosis or replace clinician interpretation.

Clinical takeaway. Clinical role: Diagnostic ultrasound; assisted abdominal FAST acquisition and anatomical labeling

Evidence takeaway. Evidence from the reviewed source record: FDA review includes a retrospective FAST labeling evaluation of 82 emergency-department patients and 229 loops, plus a separate 20-patient clinical bench evaluation. These are anatomical-labeling studies, not evidence of improved trauma outcomes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Diagnostic ultrasound; assisted abdominal FAST acquisition and anatomical labeling
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Image acquisition support and anatomical labeling
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Live ultrasound from compatible Lumify transducers; FAST Auto Assist uses S4-1 or C5-2 abdominal imaging
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Ultrasound images and FAST organ/zone labels for right upper quadrant, left upper quadrant and suprapubic views
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Healthcare environments; FAST Auto Assist is limited to adults
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Qualified healthcare professionals trained in ultrasound
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
FAST Auto Assist is Android-only, adult-limited and available with S4-1/C5-2 transducers. Anatomical labels do not establish free-fluid diagnosis or replace clinician interpretation.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
FDA review includes a retrospective FAST labeling evaluation of 82 emergency-department patients and 229 loops, plus a separate 20-patient clinical bench evaluation. These are anatomical-labeling studies, not evidence of improved trauma outcomes.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA review includes a retrospective FAST labeling evaluation of 82 emergency-department patients and 229 loops, plus a separate 20-patient clinical bench evaluation. These are anatomical-labeling studies, not evidence of improved trauma outcomes.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Retrospective zone-detection sensitivity ranged from 83.3% to 96.1% across zones; organ-label sensitivity ranged from 82.3% to 98.6% across organs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

82 patients, 229 loops, clinician reference; category-specific ranges, not sensitivity for free fluid or a single product-wide endpoint.

Reported specificity
Retrospective zone-detection specificity ranged from 90.2% to 96.0%; organ-label specificity ranged from 89.0% to 96.0%
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Category-specific anatomical-labeling results from 82 patients and 229 loops; not free-fluid specificity.

Overall FAST zone-detection accuracy

86 %

  • EndpointAgreement with clinician-reference FAST zone labels
  • Population82 emergency-department patients aged 18-89 with suspected free fluid; 229 ultrasound loops
  • Tested versionFAST Auto Assist evaluated in K252558; release number not stated

K252558 FAST Auto Assist retrospective labeling evaluation

  • DesignRetrospective anatomical-labeling performance study; test sites separate from training sites
  • PopulationEmergency-department patients with suspected free fluid; 229 loops
  • Scopeexact submission
  • Tested versionK252558 FAST Auto Assist
  • Samplen=82
  • IndependenceIndependence not established

K252558

Separate limited 20-patient clinical bench evaluation is also described. Independent test data do not establish independent study sponsorship.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Live ultrasound from compatible Lumify transducers; FAST Auto Assist uses S4-1 or C5-2 abdominal imaging

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Lumify Diagnostic Ultrasound System: K252558 decision and 510(k) summary

  2. Routing

    Source context, not route validation: The current Lumify app describes DICOM Store, Modality Performed Procedure Step and Storage Commitment support

    Scope: Product family. Current family documentation does not establish the supported phone, OS or interface configuration for a purchased K252558 system.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · Lumify app

  3. AI processing

    Source context, not route validation: Compatible mobile device application with USB-connected transducer; system supports Android and iOS, but FAST Auto Assist is Android-only

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · Lumify Diagnostic Ultrasound System: K252558 decision and 510(k) summary

  4. Returned objects

    Source context, not route validation: Ultrasound images and FAST organ/zone labels for right upper quadrant, left upper quadrant and suprapubic views

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · Lumify Diagnostic Ultrasound System: K252558 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images and FAST organ/zone labels for right upper quadrant, left upper quadrant and suprapubic views

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · Lumify Diagnostic Ultrasound System: K252558 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Compatible mobile device application with USB-connected transducer; system supports Android and iOS, but FAST Auto Assist is Android-only
  • Exact FDA submission
  • Checked 2026-09-05
Integration
The current Lumify app describes DICOM Store, Modality Performed Procedure Step and Storage Commitment support
  • Product family
  • Checked 2026-09-05

Current family documentation does not establish the supported phone, OS or interface configuration for a purchased K252558 system.

Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Monitoring
Philips' coordinated vulnerability disclosure policy states a global product security officer network, PGP-based reporting, acknowledgement within 2 business days, report tracking, updates every 2-3 weeks, a 90-day resolution aim and customer notification.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The policy names Philips generally and does not scope these commitments to any specific product release; exact-release scope is not established.

DICOM workflow

Current Lumify app lists DICOM Store, MPPS and Storage Commitment

product family · checked 2026-09-05

FAST platform restriction

Android with S4-1 or C5-2 transducer

exact submission · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252558
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Abdomen; Heart/Cardiovascular; Obstetric/Gynecologic; Musculoskeletal; Lung; Small parts
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

System indications span multiple organs, including fetal/obstetric, abdominal, pediatric, cephalic, urologic, gynecologic, cardiac, vascular, musculoskeletal and lung imaging. FAST Auto Assist is abdominal only.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
15Fields reviewed
9Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

NCT03486444 concerns next-generation ultrasound education and care; stored metadata screened, but exact FAST Auto Assist/version linkage was not established. Live registry page returned a JavaScript shell; no trial results promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, literature index, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    A regional Philips subscription page did not establish current US pricing or inclusion of this FAST feature, hardware and support.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Philips Lumify reimbursement guide CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Philips' undated Lumify reimbursement guide describes general ultrasound claim structure; it names Lumify but not this clearance or any coverage, so it is kept as a lead. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Required local onboarding, competency assessment and FAST-specific training package were not established.

8 sources - 3 history items

Source ledger

  1. K252558 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Lumify Diagnostic Ultrasound System: K252558 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  7. Lumify app

    Philips - Accessed 2026-09-05

    Scope: integration, implementation

  8. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K252558 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260844

ACUSON Sequoia Diagnostic Ultrasound System;ACUSON Sequoia Select Diagnostic Ultrasound System;ACUSON Origin Diagnostic Ultrasound System;ACUSON Origin ICE Diagnostic Ultrasound System

Siemens Medical Solutions USA, Inc.

Authorized purpose: ACUSON Sequoia, Select, Origin, and Origin ICE diagnostic ultrasound systems acquire and display the labeled fetal, abdominal, pediatric, neonatal, cephalic, small-part, obstetric, cardiac, transesophageal, intracardiac, vascular, and musculoskeletal examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; transesophageal and intracardiac applications
Decision
2026-06-16
FDA-cleared K260300

WatchMate Software

Anumana, Inc.

Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.

Modality
Ultrasound
Anatomy
Heart and left atrial appendage
Decision
2026-06-15
FDA-cleared K260780

HeartFocus

Deski

Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-06-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history